His-Li mouse, the unique humanized mouse model resembling human liver and immune systems

Informations projet

His-Li mouse

N° de convention de subvention: 867383

DOI

10.3030/867383

Projet clôturé

Date de signature de la CE 6 Mai 2019

Date de début 1 Juin 2019

Date de fin 30 Septembre 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

TRANSCURE BIOSERVICES SAS
France

Periodic Reporting for period 1 - His-Li mouse (His-Li mouse, the unique humanized mouse model resembling human liver and immune systems)

Période du rapport: 2019-06-01 au 2019-09-30

Résumé du contexte et des objectifs généraux du projet

Founded in 2012 and headquartered in Archamps (France), TransCure bioServices is a Contract Research Organisation (CRO) offering the best-in-class in vivo pharmacology preclinical services currently covering multiple areas of Immunology, such as Cancer/Immuno-oncology, HIV, Inflammatory Bowel Diseases and Vaccines. Their mission is to bridge the technology gap between preclinical models and human studies by developing the first and most accurate mouse model for reliable preclinical drug testing: the HIS-Li mouse platform. TransCure’s game-changing innovation is a humanized mouse model that fully reflects the human immune and liver systems. HIS-Li mouse will enable a smarter, faster and more cost-effective drug development process. The team is now focused on the optimization of the HIS-Li mouse generation protocol and the creation of disease models for therapy discovery. These models will be validated in collaboration with acknowledged pharmaceutical companies for their accuracy and reliability in preclinical testing, laying the ground for initial commercialization in Europe.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During the feasibility assessment, TransCure defined the users’ requirements for HIS-Li mouse optimization, reviewed the development plan, defined the scale-up activities, and scouted for key stakeholders to support in the validation stages. The Company evaluated the target market segments and opportunities, defined the Total and Serviceable Addressable markets and established the commercialisation strategy. The Phase 1 feasibility assessment showed that the HIS-Li project is technically and commercially viable. The EIC Accelerator Phase 2 funding will provide an important source of non-dilutive funding to complete the planned activities.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Between 2015 and 2050, the proportion of the world's population over 60 years is projected to nearly double from 12% to 22%, reaching 2.1 B in 2050; about 434 million people will be older than 80 years. The incidence of killer diseases such as cardiovascular diseases, diabetes, respiratory diseases, etc. - mostly age-related - is expected to increase accordingly. This demographic transformation will increase demand for effective treatments, and calls for smarter drug development procedures. TransCure technology – the HIS-Li mouse – will be a uniquely efficient solution to respond to these unmet societal and medical needs by accelerating drug discovery and development, as it will enable smarter and more cost-effective market delivery of new drugs while at the same time increasing their safety. While providing huge economic benefits to the drug development industry, the HIS-Li mouse will have a wider societal impact by enabling discovery of treatments for untreatable diseases, thus contributing to saving millions of lives.

his-li-diagram.png